|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
| ||||||||||||||||||||
Files in this Data Supplement:
Fig. S1. Deletion of the EF-hand or GAS2 motif in Shot impairs its interaction with Kra. S2 cells transiently expressing both HA-Kra and Shot L(A)-GFP, Shot L(A)-ΔGAS2-GFP or Shot L(A)-ΔEF-GFP were lysed. Soluble extracts were immunoprecipitated with an anti-GFP antibody. The precipitates were analyzed by western blot analysis using anti-HA and anti-α-tubulin antibodies. HA-Kra and endogenous α-tubulin were also detected in 5% of the total extracts to control for protein levels.
Fig. S2. kra and shot genetically interact with slit at the CNS midline. (A-D) The CNS of stage 16-17 embryos stained with mAb 1D4 (anti-Fasciclin II). Wild-type embryos show three parallel fascicles of longitudinal axons on each side of the ventral midline; these fascicles never approach or cross the midline (Fig. 4D). (A) In slit2/+ heterozygous embryos, the longitudinal axons ectopically cross the midline. (B,C) The slit2/+ phenotype is significantly enhanced when one copy of kra or shot is also removed in slit2/+; kra2/+ (B) or slit2,+/+,shot3 (C) transheterozygous embryos, respectively. In kra2/+ or shot3/+ control embryos, the longitudinal axon tracts appear the same as in the wild-type (Fig. 5A,B). (D) A further enhancement in ectopic midline crossing is observed in slit2,+/+,shot3; kra2/+ transheterozygous embryos. Anterior is to the top. (E) Quantification of the midline crossing frequency per segments in each of the indicated genotypes (slit2/+, n=220; slit2/+; kra2/+, n=486; slit2,+/+,shot3, n=445; slit2,+/+,shot3; kra2/+, n=350). Statistically significant differences are denoted on the top of bars by an asterisk (control, slit/+; P<0.001). Scale bar: 10 μm.
Fig. S3. Expression of Repo and Wrapper is normal in kra mutant embryos. Stage 16 wild-type (A,B) and kra mutant (C,D) embryos carrying the apC-tau-lacZ marker were doubly stained with anti-β-galactosidase (red) and either anti-Repo (green) or anti-Wrapper (green). (A) Repo is expressed by all CNS glial cells except for the midline glia in wild-type embryos. (B) Wrapper is specifically expressed by the midline glia in wild-type embryos. (C,D) In kra1/kra2 embryos, apparently normal levels and patterns are observed for Repo (C) and Wrapper (D) even in the segments where Ap axons ectopically cross the midline (arrowheads). Scale bar: 10 μm.
Fig. S4. eIF2β is required for midline axon guidance. (A) The genomic structure of the eIF2β locus. The eIF2β gene is located at 69C4 on the third chromosome. The insertion sites of P-element are indicated as inverted triangles. The transposons of G6433 and G6414 (purchased from Genexel, Korea) are inserted at -81 and -69, respectively, of the eIF2β open reading frame (ORF). Molecular lesions of the deletion lines eIF2β1 and eIF2β2 that were generated by the imprecise excision of G6414 and G6433, respectively, are indicated. Homozygotes and transheterozygotes for eIF2β1, eIF2β2 and Df(3L)ED4486 are embryonic lethal. For the predicted transcripts of eIF2β and its neighboring gene CG10627, black boxes represent coding regions and white boxes represent untranslated regions; predicted translation initiation and stop sites are indicated. (B-E) Mutations in eIF2β lead to defects in midline axon repulsion. (B) A stage 16 eIF2β mutant embryo carrying the apC-tau-lacZ marker was stained with anti-β-galactosidase. The Ap axons abnormally cross the midline in this embryo (white arrows). (C) A stage 13 eIF2β mutant embryo was stained with mAb 1D4. The pCC axons also show ectopic midline crossing (black arrows). (D) A stage 16 eIF2β mutant embryo was stained with mAb 1D4. Axons from the innermost longitudinal tract frequently cross the midline (black arrow). Scale bar: 10 μm. Anterior is to the top. (E) Quantification of midline crossing defects per segments in each of the indicated genotypes (eIF2β1/+, n=280 segments; eIF2β2/+, n=224; eIF2β1/eIF2β2, n=650; eIF2β1/eIF2β1, n=496; eIF2β2/Df(3L)ED4486, n=344). Scale bar: 10 μm.
| ||||||||||||||||||||